Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or de-intens...
L. Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al.· Research Square· 0 citations
Although a heritable component is implicated in ~10% of melanomas, the prevalence and functional relevance of germline pathogenic variants (gPVs) in unselected patients remains unknown. We evaluated 701 patients with melanoma who underwent tumor-normal MSK-IMPACT sequencing (2015–2023) and germline analysis of ≥76 ca...
S. Lochrin, H. Walch, Y. Kemel et al.· npj Genomic Medicine· 0 citations
The data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Paolo Manca, H. Walch, Jierui Xu et al.· Cancer Cell· 1 citation
CUP melanomas in self-ID POC had lower median TMB and were more likely to be pan-wildtype, reflecting differences in pathogenesis, and larger scale studies are needed to validate these findings.
J. Ross, V. Weir, Leore Lavin et al.· Journal of American Academy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
